Trial · NCT00440011

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

NCT00440011, Phase 4, Completed, Allergan; results first posted 2008-09-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%. Trials, record NCT00440011. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00440011

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
NCT number: NCT00440011
Status: Completed
Phases: Phase 4
Enrollment: 266 participants, actual
Lead sponsor: Allergan
Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03% eye drops, travoprost 0.004% eye drops
First posted: 2007-02-26
Last updated: 2019-04-25
Results first posted: 2008-09-26

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	Month 3	Intraocular Pressure
Secondary	Tolerability - Conjunctival Hyperemia	Month 3	Conjunctival Hyperemia: Number of participants with at least 1 grade increase in severity from baseline. A five grade scale from 0 to 3 (0 = none, +0.5 = trace, 1 = mild, 2 = moderate, 3 = severe)

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	Month 3		mm Hg	MEAN
SECONDARY	Tolerability - Conjunctival Hyperemia	Month 3		participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Intraocular Pressure (IOP)	Bimatoprost	17	Standard Deviation 3.1	mm Hg
Intraocular Pressure (IOP)	Travoprost	17.5	Standard Deviation 2.6	mm Hg
Tolerability - Conjunctival Hyperemia	Bimatoprost	15		participants
Tolerability - Conjunctival Hyperemia	Travoprost	22		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bimatoprost	131
Overall Study	STARTED	Travoprost	135
Overall Study	COMPLETED	Bimatoprost	127
Overall Study	COMPLETED	Travoprost	132
Overall Study	NOT COMPLETED	Bimatoprost	4
Overall Study	NOT COMPLETED	Travoprost	3

Source ClinicalTrials.gov

Adverse events72

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Ocular Hyperaemia	Eye disorders	Bimatoprost	4	131
other	Ocular Hyperaemia	Eye disorders	Travoprost	1	133
other	Eye Pruritus	Eye disorders	Bimatoprost	3	131
other	Eye Pruritus	Eye disorders	Travoprost	1	133
other	Conjunctival Hyperaemia	Eye disorders	Bimatoprost	1	131
other	Conjunctival Hyperaemia	Eye disorders	Travoprost	2	133
other	Punctate keratitis	Eye disorders	Bimatoprost	1	131
other	Punctate keratitis	Eye disorders	Travoprost	2	133
other	Eye Irritation	Eye disorders	Bimatoprost	2	131
other	Eye Irritation	Eye disorders	Travoprost	0	133

1 to 10 of 72Source ClinicalTrials.gov

See all 72 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bimatoprost
Total, all-cause mortality	Travoprost
Total, other adverse events	Bimatoprost	21	131
Total, other adverse events	Travoprost	22	133
Total, serious adverse events	Bimatoprost	1	131
Total, serious adverse events	Travoprost	0	133

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19726422	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Bimatoprost vs Travoprost: Tolerability - Conjunctival Hyperemia	Trial comparisons
Bimatoprost vs Travoprost: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00440011

GET https://conductscience.org/api/trials/v1/NCT00440011/events?page=2

API reference For AI assistants